4//SEC Filing
Bogue Zachary 4
Accession 0001209191-21-028016
CIK 0001601830other
Filed
Apr 21, 8:00 PM ET
Accepted
Apr 22, 7:28 PM ET
Size
36.0 KB
Accession
0001209191-21-028016
Insider Transaction Report
Form 4
Bogue Zachary
Director10% Owner
Transactions
- Other
Common Stock
2021-04-20−5,941,120→ 0 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-04-20−3,771,996→ 0 total(indirect: See footnote)→ Common Stock (3,771,996 underlying) - Conversion
Series B Preferred Stock
2021-04-20−3,220,788→ 0 total(indirect: See footnote)→ Common Stock (3,220,788 underlying) - Other
Common Stock
2021-04-20−3,951,141→ 0 total(indirect: See footnote) - Other
Class A Common Stock
2021-04-20+3,951,141→ 3,951,141 total(indirect: See footnote) - Conversion
Common Stock
2021-04-20+5,941,120→ 5,941,120 total(indirect: See footnote) - Other
Class A Common Stock
2021-04-20+5,941,120→ 5,941,120 total(indirect: See footnote) - Other
Common Stock
2021-04-20−3,726,963→ 0 total(indirect: See footnote) - Conversion
Common Stock
2021-04-20+3,951,141→ 3,951,141 total(indirect: See footnote) - Other
Class A Common Stock
2021-04-20+3,726,963→ 3,726,963 total(indirect: See footnote) - Conversion
Series C Preferred Stock
2021-04-20−1,095,529→ 0 total(indirect: See footnote)→ Common Stock (1,095,529 underlying) - Conversion
Series C Preferred Stock
2021-04-20−730,353→ 0 total(indirect: See footnote)→ Common Stock (730,353 underlying) - Conversion
Common Stock
2021-04-20+3,726,963→ 3,726,963 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-04-20−1,073,595→ 0 total(indirect: See footnote)→ Common Stock (1,073,595 underlying) - Conversion
Series D Preferred Stock
2021-04-20−3,726,963→ 0 total(indirect: See footnote)→ Common Stock (3,726,963 underlying)
Footnotes (5)
- [F1]Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date.
- [F2]Represents shares held of record by Data Collective IV, L.P. ("DCVC IV"). Data Collective IV GP, LLC ("DCVC IV GP") is the general partner of DCVC IV and has sole voting and dispositive power with regard to the shares held by DCVC IV. Matthew Ocko and Zachary Bogue are the managing members of DCVC IV GP and share voting and dispositive power with respect to the shares held by DCVC IV. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any.
- [F3]Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO.
- [F4]Represents shares held of record by DCVC Opportunity Fund II, L.P. ("DCVC Opp Fund II"). DCVC Opportunity Fund II GP, LLC ("DCVC Opp Fund II GP") is the general partner of DCVC Opp Fund II and has sole voting and dispositive power with regard to the shares held by DCVC Opp Fund II. Matthew Ocko and Zachary Bogue are the managing members of DCVC Opp Fund II GP and share voting and dispositive power withrespect to the shares held by DCVC Opp Fund II. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any.
- [F5]Represents shares held of record by DCVC V, L.P. ("DCVC V"). DCVC V GP, LLC ("DCVC V GP") is the general partner of DCVC V and has sole voting and dispositive power with regard to the shares held by DCVC V. Matthew Ocko and Zachary Bogue are the managing members of DCVC V GP and share voting and dispositive power with respect to the shares held by DCVC V. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such shares and this report shall not be deemed an admission that such person is the beneficial owner of such shares, except to the extent of such person's indirect pecuniary interest therein, if any.
Documents
Issuer
RECURSION PHARMACEUTICALS, INC.
CIK 0001601830
Entity typeother
Related Parties
1- filerCIK 0001836157
Filing Metadata
- Form type
- 4
- Filed
- Apr 21, 8:00 PM ET
- Accepted
- Apr 22, 7:28 PM ET
- Size
- 36.0 KB